Skip to main
STTK
STTK logo

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc is strategically positioned within the burgeoning market for inflammatory bowel disease (IBD), projected to reach $26.8 billion in sales by 2028, which suggests a favorable financial landscape for its product candidates. The company’s lead programs, including SL-325 and its half-life extended version SL-425, aim to leverage the significant insights related to the TL1A/DR3 signaling pathway, demonstrating improved therapeutic potential over existing treatments in preclinical studies. With a robust financial foundation evidenced by a cash runway extending into 2027, Shattuck Labs is well-equipped to advance its innovative therapeutic candidates in a promising market segment.

Bears say

Shattuck Labs Inc. faces significant challenges in its financial outlook due to the risk of failed or inconclusive clinical trials, which could severely restrict the company's ability to secure adequate funding necessary for drug development. The recent halt in development of SL-172154, coupled with the pivot towards an autoimmune-focused pipeline with early-stage assets, has created a lack of near-term value drivers, increasing uncertainty for investors. Additionally, the prevailing negative sentiment surrounding the CD47 space in oncology may further hinder the company's clinical progress and overall valuation.

Shattuck Labs (STTK) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 6 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.